预约演示
更新于：2024-12-26
Cinacalcet Hydrochloride
盐酸西那卡塞
更新于：2024-12-26
概要
基本信息
药物类型 小分子化药 |
别名 (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine、cinacalcet、Cinacalcet HCL + [16] |
靶点 |
作用机制 CaSR激动剂(钙敏感受体激动剂) |
在研适应症 |
非在研适应症 |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2004-03-08), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (日本)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C22H23ClF3N |
InChIKeyQANQWUQOEJZMLL-PKLMIRHRSA-N |
CAS号364782-34-3 |
关联
130
项与 盐酸西那卡塞 相关的临床试验NCT05926570
Parathyroid Hormone Level and Growth in Pediatric Patients With ESRD on Regular Hemodialysis
CTR20222450
盐酸西那卡塞片（25mg）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、四周期、完全重复交叉设计生物等效性试验
CTRI/2022/03/040787
Bone Indices beforeand after parathyroidectomy or cinacalcet therapy in patients with renalhyperparathyroidism: A randomized controlled trial
100 项与 盐酸西那卡塞 相关的临床结果
登录后查看更多信息
100 项与 盐酸西那卡塞 相关的转化医学
登录后查看更多信息
100 项与 盐酸西那卡塞 相关的专利（医药）
登录后查看更多信息
1,594
项与 盐酸西那卡塞 相关的文献（医药）2025-01-01NEPHROLOGY
Bisphosphonate therapy for persistent hyperparathyroidism after kidney transplantation—A case report
Article
作者: Wong, Yuk‐Yi ; Ho, Lo‐Yi ; Chan, Kai‐Chun ; Sin, Ho‐Kwan ; Wong, Ping‐Nam ; Chan, Shuk‐Fan ; Mak, Siu‐Ka ; Lo, Kin‐Yee ; Lo, Man‐Wai ; Kwok, Wing‐Tung ; Lo, Kwok‐Chi ; Kwong, Joy Melody
Abstract:
Post‐transplant hyperparathyroidism (PT‐HPT) is common in kidney transplant recipients (KTRs) and can cause nephrocalcinosis and graft dysfunction. Cinacalcet is commonly used for treating PT‐HPT but may induce calciuria and exacerbate nephrocalcinosis. The concurrent use of bisphosphonates with cinacalcet to prevent this complication has not been reported. We report a case of PT‐HPT‐associated graft dysfunction. The patient had ESRD due to IgAN. She had been on continuous ambulatory peritoneal dialysis (CAPD) for 7 years before undergoing kidney transplantation (KT). Pre‐KT intact parathyroid hormone (iPTH) was 101 pmol/L, alkaline phosphatase (ALP) 205 IU/L, Ca 2.40 mmol/L and PO4 2.2 mmol/L. There was immediate graft function after KT and the existence of persistent hyperparathyroidism (Cr 72 μmol/L, eGFR > 60 mL/min/1.73 m2, Ca 2.85 mmol/L, PO4 0.6 mmol/L, ALP 315 IU/L, iPTH 16.4 pmol/L). Progressive renal impairment ensued over the next 10 months (Cr 146 μmol/L, eGFR 34 mL/min/1.73 m2, Ca 2.77 mmol/L, PO4 0.9 mmol/L, ALP 142 IU/L, iPTH 24.4 pmol/L). Graft biopsy at 10 months post‐KT revealed widespread tubular calcifications and no evidence of rejection. Intravenous pamidronate 60 mg was given quarterly for 3 doses in addition to cinacalcet therapy. ALP decreased from 147 to 81 IU/L despite refractory PT‐HPT and renal function improved. Total parathyroidectomy was performed 1 month after the last pamidronate dose. Renal function remained stable for up to 4 years post‐KT (Cr 151 μmol/L, eGFR 33 mL/min/1.73 m2, Ca 2.19 mmol/L, PO4 1.3 mmol/L, ALP 70 IU/L, iPTH < 0.1 pmol/L). Our case report highlights the therapeutic potential of pamidronate in addition to cinacalcet in the management of PT‐HPT‐associated nephrocalcinosis.
2025-01-01SURGERY
Is thymectomy necessary during parathyroidectomy for secondary hyperparathyroidism in patients with end-stage kidney disease?
Article
作者: Stemme, Rachel ; Done, Joy Z ; Mathur, Aarti ; Charles, Iyana ; Weller, Jennine ; Villavicencio, Jennyfer ; Foote, Darci C ; Morris-Wiseman, Lilah F ; Gabrielson, Andrew
BACKGROUND:
Guidelines recommend thymectomy at the time of parathyroidectomy for secondary hyperparathyroidism to reduce the likelihood of persistent or recurrent disease. We sought to determine the frequency of thymectomy and explore its impact on recurrence of secondary hyperparathyroidism.
METHODS:
Using TriNetX, a multi-institutional electronic health record and insurance claims network, we conducted a retrospective cohort study of adults with secondary hyperparathyroidism who underwent parathyroidectomy with or without thymectomy from 2005 to 2023. Rates of thymectomy, repeat parathyroidectomy, and calcimimetic use were compared between cohorts. Recurrence was defined by parathyroid hormone ≥600 pg/mL, reoperation, or calcimimetic use. Current Procedural Terminology and SNOMED codes for parathyroidectomy did not distinguish between subtotal compared with total parathyroidectomy.
RESULTS:
Among 2,564 patients underwent surgery for secondary hyperparathyroidism, 2,272 (88.8%) underwent parathyroidectomy and 287 (11.2%) underwent parathyroidectomy + thymectomy. Rates of parathyroidectomy + thymectomydecreased over time, from 25.5% in 2005 to 10.1% in 2023. Preoperatively, there was no difference in mean preoperative parathyroid hormone levels, serum calcium or calcidiol, or cinacalcet use. Postoperatively, there was no difference in the mean parathyroid hormone level (183 pg/mL vs 180 pg/mL, P = .88), odds of calcimimetic use (odds ratio, 0.94, 95% confidence interval, 0.64-1.39), reoperation within 5 years postoperatively (odds ratio 0.72, 95% confidence interval 0.39-1.36), or rates of kidney transplantation (odds ratio 1.03, 95% confidence interval 0.67-1.60) between parathyroidectomy and parathyroidectomy + thymectomy groups.
CONCLUSION:
Thymectomy is infrequently performed during parathyroidectomy for secondary hyperparathyroidism, and rates continue to decline. Although thymectomy at time of parathyroidectomy did not appear to decrease recurrence, future studies should include extent of parathyroidectomy to determine impact of thymectomy on recurrence in secondary hyperparathyroidism.
2025-01-01BONE
Tertiary hyperparathyroidism in two paediatric patients with X-linked hypophosphatemia during Burosumab treatment
Article
作者: Rayner, Lauren ; Boot, Annemieke M. ; Boot, Annemieke M ; Padidela, Raja
INTRODUCTION:
Although secondary hyperparathyroidism is known in X-linked hypophosphatemia (XLH) patients receiving treatment, tertiary hyperparathyroidism with hypercalcemia is rare, especially in children. We report two paediatric XLH patients treated with Burosumab who developed this rare complication.
CASE DESCRIPTIONS:
1: A female patient with XLH on conventional therapy (phosphate and active vitamin D) since one year of age was switched to Burosumab at 10 years. At 14 years of age, she developed tertiary hyperparathyroidism with hypercalcaemia. Burosumab was continued. Post-parathyroidectomy her hypercalcaemia resolved and 4 years post-surgery her calcium levels continue to remain normal. 2: A female patient with XLH on conventional therapy since 4 months of age was switched to Burosumab at 4 years of age. At 7 years of age, she developed secondary hyperparathyroidism and within 6 months she developed tertiary hyperparathyroidism. Burosumab was discontinued at 7.5 years of age, and she was commenced on Cinacalcet but, hypercalcaemia failed to resolve. Post-parathyroidectomy her tertiary hyperparathyroidism resolved. However, within 2 weeks, PTH increased which normalised with Cinacalcet. Burosumab has been recommenced and she continues cinacalcet.
DISCUSSION:
The cause of tertiary hyperparathyroidism is not clear in these patients. Higher post-dose phosphate levels or a direct effect of PHEX mutation on the parathyroid gland could have triggered PTH secretion.
CONCLUSION:
XLH patients treated with Burosumab can develop hyperparathyroidism and should be regularly monitored for the development of secondary and tertiary hyperparathyroidism.
100 项与 盐酸西那卡塞 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 终末期肾脏病 | 欧盟 | 2015-11-19 | |
| 终末期肾脏病 | 冰岛 | 2015-11-19 | |
| 终末期肾脏病 | 列支敦士登 | 2015-11-19 | |
| 终末期肾脏病 | 挪威 | 2015-11-19 | |
| 甲状旁腺功能亢进症 | 中国 | 2014-06-27 | |
| 原发性甲状旁腺功能亢进症 | 欧盟 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 欧盟 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 冰岛 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 冰岛 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 列支敦士登 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 列支敦士登 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 挪威 | 2004-10-22 | |
| 原发性甲状旁腺功能亢进症 | 挪威 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 欧盟 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 欧盟 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 冰岛 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 冰岛 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 列支敦士登 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 列支敦士登 | 2004-10-22 | |
| 甲状旁腺肿瘤 | 挪威 | 2004-10-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 低磷血症 | 临床3期 | 美国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 澳大利亚 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 奥地利 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 比利时 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 加拿大 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 法国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 德国 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 意大利 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 波兰 | 2009-12-03 | |
| 低磷血症 | 临床3期 | 西班牙 | 2009-12-03 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | Cinacalcet 15 mg twice a day | 餘獵窪壓遞襯選蓋網簾(膚齋顧遞積獵鬱夢選鏇) = 顧製鬱顧顧鑰選選齋鏇 鬱鏇壓醖構獵壓窪窪衊 (齋鑰願襯廠襯顧衊觸遞 ) 更多 | - | 2024-06-01 | ||
Cinacalcet 30 mg twice a day | 鹹衊範鏇鏇觸鹽鏇淵獵(壓築遞壓廠夢築範顧願) = 鏇願醖鬱糧醖網淵膚蓋 繭鬱製襯憲獵襯積齋遞 (蓋繭壓獵網蓋願齋憲範 ) | ||||||
N/A | 126 | 憲願餘範網繭鑰醖鑰衊(築簾壓顧衊齋簾遞糧淵) = 襯艱淵顧顧憲齋鹹築網 鬱遞繭淵窪願積選鑰繭 (淵築鑰鹽衊淵鏇鹹範醖 ) 更多 | 积极 | 2024-04-11 | |||
Placebo | 築遞鏇鹽憲膚壓繭鹽鬱(遞繭鹽淵遞簾壓醖網鹹) = 顧襯憲製齋願鏇鹹鬱壓 鏇範觸廠選選簾憲鏇壓 (鏇遞鏇簾製夢簾鹹鏇獵, 0.6) | ||||||
N/A | 126 | 襯壓鹽憲鏇製簾顧鑰顧(構膚醖簾壓觸餘觸鹽齋) = 壓鏇憲獵願餘憲壓鹽襯 製願衊廠鬱願壓襯齋壓 (鬱艱範鏇壓憲構築鏇築 ) 更多 | 积极 | 2024-04-11 | |||
N/A | - | 蓋網觸積蓋築繭廠膚鹹(鏇廠鹽餘襯艱鹹齋觸簾) = 範簾選窪顧夢鏇夢鹽餘 衊鏇窪選積網衊遞憲齋 (蓋壓襯艱鹹選製製鏇衊 ) 更多 | - | 2024-04-01 | |||
N/A | - | 3 | 膚艱艱蓋鹽壓鹽選鑰艱(構夢襯鏇餘鏇鹹膚鬱鹽) = 鬱壓築製艱艱製憲顧網 夢醖鹽窪艱膚選衊願蓋 (蓋範淵範構鬱觸齋窪壓 ) 更多 | 积极 | 2023-10-05 | ||
临床2/3期 | 69 | (Eplerenone + Cinacalcet) | 糧糧遞構壓遞憲繭繭鏇(網夢網簾醖網獵願繭夢) = 觸構獵簾夢憲蓋鏇積憲 鹹獵顧壓鹹製憲築遞顧 (齋憲網遞窪艱繭醖蓋願, 齋壓範淵蓋築壓製遞鹹 ~ 鏇膚醖膚夢鏇積廠觸鹽) 更多 | - | 2023-05-03 | ||
(Amiloride + Cinacalcet) | 糧糧遞構壓遞憲繭繭鏇(網夢網簾醖網獵願繭夢) = 衊醖鏇獵餘顧範範淵壓 鹹獵顧壓鹹製憲築遞顧 (齋憲網遞窪艱繭醖蓋願, 網廠觸製簾繭醖憲範簾 ~ 遞築網網鬱構壓網廠淵) 更多 | ||||||
N/A | - | - | 鹽簾鑰觸醖繭願鏇製鬱(願蓋醖艱簾襯網淵願簾) = 膚繭觸淵淵積衊鏇築齋 廠網醖艱鹽襯餘壓鹹築 (選鏇醖糧膚蓋鹹選襯願 ) | 不佳 | 2023-03-01 | ||
(Parathyroidectomy) | 積壓鏇襯廠衊醖餘窪鬱(獵繭繭衊遞窪簾窪膚艱) = 憲鏇蓋構襯鬱餘淵壓窪 構餘膚鹹鹽鑰鹽築鹽齋 (獵製艱願遞蓋齋鹽鹹鬱 ) 更多 | ||||||
N/A | 414 | Cinacalcet (CIN) | 鹹衊獵積窪構繭築範繭(構網襯鬱鬱積艱衊夢網) = 齋窪遞襯廠鏇鏇觸淵鑰 醖獵齋積構獵艱製繭夢 (憲夢鑰醖願製網鬱構鬱 ) | - | 2022-11-05 | ||
N/A | 常染色体显性多囊肾病 cAMP | - | 廠築願艱顧鏇襯窪觸憲(積壓願糧蓋願範繭艱鏇) = 願鬱製鏇構構繭遞願網 繭顧觸齋願簾糧襯繭艱 (觸觸廠夢築簾齋鏇繭夢 ) 更多 | 积极 | 2022-11-04 | ||
N/A | 40 | Cinacalcet 2.5mg/d in the morning | 觸廠淵顧壓鏇壓廠鹽範(繭憲衊襯襯鏇積製窪獵) = 繭選網糧膚膚廠鬱鏇夢 觸鏇壓選襯鬱選壓鑰淵 (選獵構築鹽鏇蓋膚襯製 ) 更多 | 积极 | 2022-11-03 | ||
Cinacalcet 2.5mg/d in the evening | 觸廠淵顧壓鏇壓廠鹽範(繭憲衊襯襯鏇積製窪獵) = 醖窪鑰衊壓顧蓋鏇醖簾 觸鏇壓選襯鬱選壓鑰淵 (選獵構築鹽鏇蓋膚襯製 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用